Piper Sandler Initiates Coverage On Elevation Oncology with Overweight Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler has initiated coverage on Elevation Oncology (NASDAQ:ELEV) with an Overweight rating and a price target of $10.
May 31, 2024 | 9:56 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler has initiated coverage on Elevation Oncology with an Overweight rating and a price target of $10, indicating a positive outlook for the stock.
The Overweight rating and $10 price target from Piper Sandler suggest a positive outlook for Elevation Oncology, likely leading to increased investor interest and a potential rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100